Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3140 | Psychological stress and adaptation at work score (PSAS) Wiki | 0.71 |
| drug4238 | Virtual Reality Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000073397 | Occupational Stress NIH | 0.32 |
| D013315 | Stress, Psychological NIH | 0.13 |
| D013577 | Syndrome NIH | 0.06 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study will be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines and treatments by allowing researchers to determine the difference between the body's immune response to natural SARS-CoV-2 infection and immunization with a SARS-CoV-2 vaccine.
Description: Measured by peptide microarray
Measure: Humoral responses to peptide antigens derived from SARS-CoV-2 structural proteins and regions of the spike protein not present in vaccines Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by binding antibody multiplex assay (BAMA)
Measure: SARS-CoV-2-specific antibody binding response rate Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by binding antibody multiplex assay (BAMA)
Measure: SARS-CoV-2-specific antibody binding response magnitude Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by binding antibody multiplex assay (BAMA)
Measure: SARS-CoV-2-specific antibody binding response epitope specificity Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by neutralizing antibody assay (NAb)
Measure: SARS-CoV-2-specific antibody neutralization response rate Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by neutralizing antibody assay (NAb)
Measure: SARS-CoV-2-specific antibody neutralization response magnitude Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by neutralizing antibody assay (NAb)
Measure: SARS-CoV-2-specific antibody neutralization response epitope specificity Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by antibody-dependent cellular cytotoxicity assay (ADCC)
Measure: SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response rate Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by antibody-dependent cellular cytotoxicity assay (ADCC)
Measure: SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response magnitude Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by antibody-dependent cellular cytotoxicity assay (ADCC)
Measure: SARS-CoV-2-specific Antibody-Dependent Cellular Cytotoxicity (ADCC) response epitope specificity Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by flow cytometry
Measure: SARS-CoV-2-specific CD4+ and CD8+ T cell responses Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by flow cytometry
Measure: SARS-CoV-2-specific CD4+ and CD8+ T cell response rate Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by flow cytometry
Measure: SARS-CoV-2-specific CD4+ and CD8+ T cell response magnitude Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by flow cytometry
Measure: SARS-CoV-2-specific CD4+ and CD8+ T cell response functional profiling Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by phenotyping and monoclonal antibody isolation
Measure: SARS-CoV-2-specific memory B cell characterization Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Tabulated overall and by group
Measure: SARS-CoV-2-specific infection presentation, including clinical course, along with demographics and corresponding medical history of participants Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by real-time reverse transcription polymerase chain reaction (RT-PCR) assay
Measure: Detection of viral RNA in nasopharyngeal or nasal swab samples Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by binding antibody multiplex assay (BAMA)
Measure: Response rate of SARS-CoV-2-specific binding antibodies in nasal samples Time: Measured through participant's last visit at Month 0, 2, 4, or 12Description: Measured by binding antibody multiplex assay (BAMA)
Measure: Response magnitude of SARS-CoV-2-specific binding antibodies in nasal samples Time: Measured through participant's last visit at Month 0, 2, 4, or 12The purpose of this study is to learn more about the acute response to infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name "coronavirus." It can cause the disease called COVID-19. The information gained from the study can be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines, other prevention strategies, and treatments.
Description: Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel
Measure: Response rate of SARS-CoV-2-specific B cells in peripheral blood samples Time: Measured through day 14Description: Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel
Measure: Magnitude of SARS-CoV-2-specific B cells in peripheral blood samples Time: Measured through day 14Description: Characterized using fluorescently labeled recombinant proteins in combination with a flow cytometry phenotyping panel
Measure: Phenotypic characterization of SARS-CoV-2-specific B cells in peripheral blood samples Time: Measured through day 14Description: Measured by binding antibody multiplex assay (BAMA)
Measure: Response rate of SARS-CoV-2-specific antibody binding in serum samples Time: Measured through day 28Description: Measured by neutralizing antibody assay (nAb)
Measure: Response rate of SARS-CoV-2-specific neutralizing antibodies in serum samples Time: Measured through day 28Description: Measured by binding antibody multiplex assay (BAMA)
Measure: Magnitude of SARS-CoV-2-specific antibody binding antibodies in serum samples Time: Measured through day 28Description: Measured by neutralizing antibody assay (nAb)
Measure: Magnitude of SARS-CoV-2-specific neutralizing antibodies in serum samples Time: Measured through day 28Description: Measured by binding antibody multiplex assay (BAMA)
Measure: Response rate of SARS-CoV-2-specific binding antibodies in nasal wash samples Time: Measured through day 28Description: Measured by binding antibody multiplex assay (BAMA)
Measure: Magnitude of SARS-CoV-2-specific binding antibodies in nasal wash samples Time: Measured through day 28Description: Measured by flow cytometry
Measure: Frequency of leukocyte populations in peripheral blood Time: Measured through day 14Description: Measured by gene expression analysis by RNA sequencing, real-time PCR, single-cell proteogenomic profiling
Measure: Transcriptional profiles of peripheral blood leukocytes Time: Measured through day 14Description: Measured by multiplexed protein detection assays and/or enzyme-linked immunosorbent assays (ELISA)
Measure: Concentration of serum cytokines and other soluble factors Time: Measured through day 28Description: Measured by flow cytometry
Measure: Response rate of SARS-CoV-2-specific CD4+ and CD8+ T cells Time: Measured through day 28Description: Measured by flow cytometry
Measure: Magnitude of SARS-CoV-2-specific CD4+ and CD8+ T cells Time: Measured through day 28Description: Measured by flow cytometry
Measure: Functional profiling, including intracellular cytokine staining, of SARS-CoV-2-specific CD4+ and CD8+ T cells Time: Measured through day 28Description: Measured by extraction of nucleic acid for analysis of microorganism RNA or DNA by qPCR and/or amplicon- or metagenomics-sequencing methods and subsequent gene and taxa-level bioinformatics analyses
Measure: Quantitation of viral RNA in nasal swabs Time: Measured through day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports